Jared Gollob sold $3.7M of KYMR
Chief Medical Officer at Kymera Therapeutics, Inc.. 59,576 shares at an average of $61.42, traded Oct 15, 2025, filed Oct 15, 2025.
Score components
- +15RoleOfficer
- +25Trade size$3.7M at market
- +10Share of holdings soldSold 35% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-240430, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 15, 2025 | MOption exercise Common Stock10b5-1 | +28,999 | $1.31 | $38k | 147,358 | Oct 15, 2025 |
| Oct 15, 2025 | MOption exercise Common Stock10b5-1 | +22,210 | $2.08 | $46k | 169,568 | Oct 15, 2025 |
| Oct 15, 2025 | SOpen-market sale Common Stock10b5-1 | -29,264 | $60.37 | $1.8M | 140,304 | Oct 15, 2025 |
| Oct 15, 2025 | SOpen-market sale Common Stock10b5-1 | -8,963 | $61.49 | $551k | 131,341 | Oct 15, 2025 |
| Oct 15, 2025 | SOpen-market sale Common Stock10b5-1 | -14,896 | $62.72 | $934k | 116,445 | Oct 15, 2025 |
| Oct 15, 2025 | SOpen-market sale Common Stock10b5-1 | -6,453 | $63.09 | $407k | 109,992 | Oct 15, 2025 |
| Oct 15, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -28,999 | $0.00 | $0 | 0 | Oct 15, 2025 |
| Oct 15, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -22,210 | $0.00 | $0 | 0 | Oct 15, 2025 |
Related signals
Other insiders at Kymera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $3.4M 30,000 shares | -4% | |
| 41Moderate | KYMRsell Kymera Therapeutics, Inc. | Brian Adams Chief Legal Officer | $744k 6,371 shares | -11% | |
| 38Weak | Kymera Therapeutics, Inc. | Jeremy G Chadwick Chief Operating Officer | $9.0M 115,977 shares | -76% | |
| 20Weak | Kymera Therapeutics, Inc. | Pamela Esposito director | $198k 2,500 shares | -100% | |
| 35Weak | Kymera Therapeutics, Inc. | Jeremy G Chadwick Chief Operating Officer | $2.1M 25,758 shares | -27% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $7.4M 81,866 shares | -2% | |
| 53Moderate | Kymera Therapeutics, Inc. | Jeremy G Chadwick Chief Operating Officer | $516k 5,958 shares | -7% | |
| 54Moderate | Kymera Therapeutics, Inc. | Jared Gollob Chief Medical Officer | $917k 10,508 shares | -8% | |
| 62Notable | Kymera Therapeutics, Inc. | Bruce N. Jacobs Chief Financial Officer | $1.1M 12,471 shares | -5% | |
| 30Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $2.7M 30,000 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.